Meta's rebrand from Facebook, much like Google's to Alphabet, was not just a name change. It was a strategic move to signal to both employees and the market that the company's ambitions extend beyond its original core product, creating the space and permission to build entirely new business lines.

Instead of perfecting a name before launch, branding agency Lexicon suggests startups should consider a rebrand as they approach their Series A funding. By this stage, the company has a much clearer understanding of its identity, market, and long-term direction, allowing for a more strategic and durable naming decision.

The most compelling reason to initiate a rebrand isn't a desire for a refresh, but when your name no longer reflects what you do. When the name is tied to a service that's now a fraction of your business, it becomes a clear, non-negotiable guardrail that forces the difficult decision to change.

BeiGene's success demonstrates a new model for biotech growth. It started in China and expanded globally, but critically maintains China as a core hub for innovation. This challenges the traditional view that biotech innovation flows primarily from the West and must be built from a US headquarters.

Driven by significant government investment, China is rapidly becoming a leader in biotech R&D, licensing, and outsourcing. This shift is a top-of-mind concern for US biotech and pharma executives, with China now involved in a majority of top R&D licensing deals.

Enviva employs a bifurcated global strategy. It leverages China's efficient talent pool and rapid clinical trial system for early discovery and proof-of-concept. It then shifts to the US and Europe for full-scale manufacturing and late-stage clinical development to gain "golden standard" regulatory approval and global market access.

The fear that changing a company name will destroy brand equity is a myth. Momentum is maintained or even accelerated when the change is launched with a compelling, enthusiastic story about the future. Focus on telling customers where you're going, not just what you're changing.

Despite media narratives of US-China tensions, Enviva's CEO reports a smooth operational experience in the US. Scientific-driven bodies like the FDA accepted their Chinese clinical data, and US-based investigators have been eager to collaborate, suggesting that on-the-ground scientific and patient-focused priorities can override political friction.

The future biotech landscape is not US vs. China, but a "multipolar" world where savvy companies operate as "hybrid biotechs." They will selectively build bridges, cherry-picking talent, capabilities, and operational models across the US, Europe, and China to accelerate development.